M&A Deal Bayer Nebido®
TU produces fewer peaks and troughs in serum T levels in comparison with the traditional T esters. Hypogonadal men treated with TU report a general sense of well-being and normal sexual function during treatment. These parameters were not different when evaluated at the https://supeco.ma/ghrp-6-5-mg-canada-peptides-dosage/ half point of injection intervals versus the end of the injection interval period. This suggests that normal physiological T values were maintained throughout the 12-week period, without major fluctuations.
As with all oily solutions, Nebido must be injected strictly intramuscularly and very slowly. Treatment with high doses of testosterone preparations commonly may reversibly stop or reduce sperm production (see also under “Possible side effects”). Abuse of testosterone, especially if you take too much of this medicine alone or with other anabolic androgenic steroids, can cause serious health problems to your heart and blood vessels (that can lead to death), mental health and/or the liver. As a consequence, androgen replacement therapy often extends over many decades. So far, the two types of testosterone treatment have not been compared for their benefits and potential drawbacks. While both types meet largely the specifications for requirements of present day androgen treatment, the higher levels achieved with TU compared to the T gel appeared to be efficacious.
Maintaining Nebido testosterone levels
The effects of buccal T on sexual functioning were comparable with those of parenteral T enanthate (Wang et al 2004b). The open questions are related to T therapy in general and apply to other T preparations as well, and relate to prostate cancer. But larger, longer-term clinical studies with more patients (comprising 6000 men followed up for 6–8 years) are required to find definitive answers on the interrelationships between T serum levels and the pathophysiology of prostate cancer. However, experts agree that it is responsible clinical practice to treat elderly hypogonadal men with T provided the existing guidelines for monitoring are followed.
Nebido injections have long been one of the most successful and commonly-used treatment programs for men who are experiencing low testosterone levels. Now that you know more about Nebido injections and what the treatments entail, you can might like to speak to one of our consultants for free at Balance My Hormones to discuss your testosterone issues and potential treatment options. These observations have been extended to larger groups of patients, confirming the results of the above study (Yassin et al 2006) (Figure 5).
- It is of note that the effect of T on erectile function may appear as late as after 12–24-weeks of administration of T (Yassin and Saad 2006b).
- Testosterone undecanoate is a valuable contribution to the treatment options of androgen deficiency.
- Adverse effects were observed in the initial studies when the dosing schedule was not yet well established and the higher frequency of administration of TU led to higher-than-normal levels of testosterone.
- Our team of healthcare experts and GMC registered doctors are licensed to UK GMC standards.
Health
So, TU appears to be a safe modality of T treatment, because of the fact that with the presently established dosage regimen, plasma T levels remain in the physiological range. The clinical efficacy of transdermal T gel on various androgen-dependent target organ systems has been well documented. The safety profile showed that prostate-specific antigen levels rose in proportion to the increase of T levels but did not exceed normal values. Skin irritation was noted in 5.5% of patients in the study (Wang et al 2004a). Transfer from one person to another was found to be insignificant (Rolf et al 2002).
After entering the peripheral circulation, TU (molecular weight 456.7 Da) is hydrolyzed to T which may then exert its androgenic activity (Horst et al 1976). Therefore, in principle, the toxicology of TU is the same as for other cleavable T fatty acid esters such as T propionate (3 carbon atoms), T enanthate (7 carbon atoms), or T cypionate (8 carbon atoms). Partsch et al (1995) compared T serum levels after single intramuscular injections of 10 mg TU or T enanthate (TE)/kg body weight in 5 long-term orchidectomized cynomolgus monkeys (Macaca fascicularis). Animals treated with TU also showed a significantly longer ejaculatory response (14-weeks) than those treated with TE (7-weeks). Local irritation at the site of injection is moderate, does not last longer than 3 days and can be minimized by administering TU slowly over a period of at least 1 minute.
To start the treatment, your doctor or medical professional will administer Nebido slowly into one of the muscles in the body. This is usually done in the ventrogluteals, deltoid, or another dense muscle area. The Nebido type of injection is very strong and will last for a while, making it more convenient to use Nebido injections than some other types of TRT injections. For testosterone products in general a common risk of increased red blood cell count, haematocrit (percentage of red blood cells in blood) and haemoglobin (the component of red blood cells that carries oxygen), were observed by periodic bloodtests. The injection interval should always be within the recommended range of 10 to 14 weeks.
Grünenthal acquires testosterone treatment NebidoTM from Bayer
Subdermal pellet implantation was among the earliest effective treatment modalities for clinical use of T and became an established form of androgen replacement by 1940 (for review (Kelleher et al 2004)). Several reports have outlined its desirable pharmacological properties but its use and merits and its complications (such as infection and extrusion) have been best documented by the group of Handelsman (Kelleher et al 2004). The product has been available in 80 countries since 2004, earning Bayer 117 million euros in sales in 2021, when the company reported total turnover of 44 billion euros from its health and agrochemicals businesses. German chemicals giant Bayer said on Thursday it was selling its male testosterone replacement drug Nebido for up to half-a-billion euros in order to concentrate on medical innovation. Additionally, Nebido injections are not intended for use in women and they are not intended for use in children or adolescents. There is no benefit in using Nebido injections for males under the age of 18.